VistaGen Therapeutics, Inc. Form 8-K January 10, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 6, 2013

Commission File Number: 000-54014

VistaGen Therapeutics, Inc. (Exact name of small business issuer as specified in its charter)

Nevada
(State or other jurisdiction of incorporation or organization)
205093315
(IRS Employer Identification No.)

384 Oyster Point Blvd, No. 8, South San Francisco, California 94080 (Address of principal executive offices)

650-244-9990 (Registrant's Telephone number)

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

ı	[] Written	communic	ations pursi	iant to Ru	ie 425 un	der the S	ecurities A	ct (1/Cl	FR 230.4	125)
ſ	[] Solicitir	ng material	pursuant to	Rule 14a-	-12 under	the Exch	nange Act (17 CFR	240.14a	-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Edgar Filing: VistaGen Therapeutics, Inc. - Form 8-K

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: VistaGen Therapeutics, Inc. - Form 8-K

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Effective January 6, 2013, Gregory A. Bonfiglio, a member of the Company's Board of Directors since 2007, resigned from his position as a Director and member of the Audit Committee to perform his new full-time responsibilities as managing principal of a recently-formed, privately-held hedge fund.

Edgar Filing: VistaGen Therapeutics, Inc. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VistaGen Therapeutics, Inc.

Date: January 10, 2013

By: /s/ Shawn K. Singh

Name: Shawn K. Singh Title: Chief Executive Officer